

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	1	of	10	Attorney Docket Number	11987-00043-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-2,811,555	10-29-1957	Larive, et al.	
	AB*	US-3,279,880	10-18-1966	Straley et al.	
	AC*	US-4,250,318	02-10-1981	Dostert et al.	
	AD*	US-4,128,654	12-05-1978	Fugitt et al.	
	AE*	US-4,327,725	05-04-1982	Cortese et al.	
	AF*	US-4,500,519	02-19-1985	Lormeau, et al.	
	AG*	US-4,705,779	11-10-1987	Madi-Szabo, et al.	
	AH*	US-4,765,989	08-23-1988	Wong et al.	
	AI*	US-4,948,801	08-14-1990	Carlson et al.	
	AJ*	US-4,977,173	12-11-1990	Brittelli et al.	
	AK*	US-5,002,937	03-26-1991	Bosies et al.	
	AL*	US-5,254,577	10-19-1993	Carlson, et al.	
	AM*	US-5,349,045	09-20-1994	Ying Jiang	
	AN*	US-5,532,255	07-02-1996	Raddatz et al.	
	AO*	US-5,561,148	10-01-1996	Gante et al.	
	AP*	US-5,565,571	10-01-1996	Barbachyn et al.	
	AQ*	US-5,654,428	08-05-1997	Barbachyn et al.	
	AR*	US-5,654,435	08-05-1997	Barbachyn et al.	
	AS*	US-5,688,792	11-18-1997	Barbachyn, et al.	
	AT*	US-5,756,732	05-26-1998	Barbachyn et al.	
	AU*	US-5,792,765	08-11-1998	Riedl, et al.	
	AV*	US-5,801,246	09-01-1998	Barbachyn et al.	
	AW*	US-5,827,857	10-27-1998	Riedl, et al.	
	AX*	US-5,910,504	06-08-1999	Hutchinson, et al.	
	AY*	US-5,922,708	07-13-1999	Riedl, et al.	
	AZ1*	US-5,929,248	07-27-1999	Barbachyn et al.	
	AA1	US-5,935,724	08-10-1999	Spillman et al.	
	AB1	US-5,972,947	10-26-1999	Tsaklakidis et al.	
	AC1*	US-5,977,373	11-02-1999	Gadwood et al.	
	AD1*	US-5,998,406	12-07-1999	Hester et al.	
	AE1*	US-6,069,160	05-30-2000	Stolle, et al.	
	AF1*	US-6,159,997	12-12-2000	Tsujita et al.	
	AG1*	US-6,218,413	04-17-2001	Hester et al.	
	AH1*	US-6,251,869	06-26-2001	Michael J. Bohanon	
	AI1*	US-6,265,178	07-24-2001	Martin, Jr.	
	AJ1*	US-6,281,210	08-28-2001	Hester, Jr.	
	AK1*	US-6,294,201-B1	09-25-2001	Kettelhoit et al	
	AL1*	US-2001/0029351-A1	10-11-2001	Falotico et al.	
	AM1*	US-2001/0046987-A1	11-29-2001	Hester et al.	
	AN1*	US-2003/0161882-A1	08-28-2003	Waterman	
	AO1*	US-2004/0162427-A1	08-19-2004	Rosentreter et al.	
	AP1*	US-6,805,881-B1	10-19-2004	Kanikanti et al.	
	AQ1*	US-6,818,243-B2	11-16-2004	Nagashima et al.	
	AR1*	US-2004/0242660-A1	12-02-2004	Straub et al.	
	AS1*	US-2005/0064006-A1	03-24-2005	Perzborn et al.	
	AT1*	US-2005/0182055-A1	08-18-2005	Berwe et al.	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	2	of	10	Attorney Docket Number	11987-00043-US

	AU1*	US-2005/0261502-A1	11-24-2005	Straub et al.	
	AV1*	US-7,034,017-B2	04-25-2006	Straub et al.	
	AW1*	US-7,045,631-B2	04-25-2006	Straub et al.	
	AX1*	US-2006/0154969-A1	07-13-2006	Rosentreter et al.	
	AY1*	US-7,078,417-B2	07-18-2006	Rosentreter et al.	
	AZ1*	US-7,109,218-B2	09-19-2006	Rosentreter et al.	
	AA2*	US-7,129,255-B2	10-31-2006	Rosentreter et al.	
	AB2*	US-2006/0258724-A1	11-16-2006	Straub et al.	
	AC2*	US-7,157,456-B2	01-02-2007	Straub et al.	
	AD2*	US-2007/0026065-A1	02-01-2007	Benke et al.	
	AE2*	US-2007/0149522-A1	06-28-2007	Thomas	
	AF2*	US-2008/0026057-A1	01-31-2008	Benke	
	AG2*	US-2008/0090815-A1	04-17-2008	Straub et al.	
	AH2*	US-2008/0200674-A1	08-21-2008	Straub et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
	BA	DE-2836305-A1	03-01-1979	Delalande SA		See US 4250318
	BB	GB-2140687	12-05-1984	Alza Corp.		
	BC	EP-0 127 902 A2	12-12-1984	E.I. Du Pont de Nemours and Co.		See US 4705799
	BD	EP-0 316 594 A1	05-24-1989	The Du Pont Merck Pharmaceutical Co.		See US 4977173
	BE	EP-0350002-A1	01-10-1990	Boehringer Mannheim GmbH		See US 5002937
	BF	EP-0 352 781 A2	01-31-1990	E.I. Du Pont De Nemours and Co.		See US 4948801
	BG	WO-93/09103 A1	05-13-1993	The Upjohn Company		See US 5565571
	BH	WO-93/23384-A1	11-25-1993	The Upjohn Company		
	BI	EP-0623615-A1	11-09-1994	Merck Patent GmbH		See US 5532255
	BJ	EP-0645376 A1	03-29-1995	Merck Patent GmbH		See US 5561148
	BK	EP-0738726-A1	10-23-1996	Bayer AG		See US 6069160
	BL	WO-97/03072-A1	01-31-1997	Boehringer Mannheim GmbH		See US 5972947
	BM	WO-97/09328 A1	03-13-1997	Pharmacia & Upjohn Company		See US 5935724
	BN	WO-97/10223-A1	03-20-1997	Pharmacia & Upjohn Company		
	BO	EP-0 785 200 A2	07-23-1997	Bayer AG		See US 5827857
	BP	DE-196 04 223 A1	08-07-1997	Bayer AG		See US 5792765
	BQ	WO-98/01446-A1	01-15-1998	Zeneca Limited		
	BR	WO-98/54161 A1	12-03-1998	Pharmacia & Upjohn Company		See US 6218413
	BS	WO-99/02525 A1	01-21-1999	Pharmacia & Upjohn Company		See US 5977373
	BT	WO-99/03846 A1	01-28-1999	Bayer Aktiengesellschaft		See Abstract
	BU	WO-99/21535-A1	05-06-1999	Bayer Aktiengesellschaft		See US 6294201 B1
	BV	WO-99/24428 A1	05-20-1999	Pharmacia & Upjohn Company		See US 5998406
	BW	WO-99/29688 A1	06-17-1999	Pharmacia & Upjohn Company		See US 6265178
	BX	WO-99/31092-A1	06-24-1999	Merck Patent GmbH		See Abstract

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	3	of	10	Attorney Docket Number	11987-00043-US

	BY	EP-0930076-A1	07-21-1999	Sankyo Company Limited		
	BZ	WO-99/37304-A1	07-29-1999	Rhone-Poulenc Rorer Pharmaceuticals		
	BA1	WO-99/37630-A1	07-29-1999	Versicor, Inc.		
	BB1	WO-99/37641-A1	07-29-1999	Bayer Aktiengesellschaft		See Abstract
	BC1	WO-99/40094-A1	08-12-1999	Bayer Aktiengesellschaft		See Abstract
	BD1	EP-0950386-A2	10-20-1999	Cordis Corporation		
	BE1	WO-99/59616-A1	11-25-1999	Pharmacia & UpJohn Company		
	BF1	WO-00/16748-A1	03-30-2000	Bayer AG		See US 6805881 B1
	BG1	WO-01/42242-A1	06-14-2001	Ortho-McNeil Pharmaceutical, Inc.		
	BH1	WO-01/44212-A1	06-21-2001	Pharmacia & UpJohn Company		See US 6281210 B2
	BI1	WO-01/46185-A1	06-28-2001	Pharmacia & UpJohn Company		See US 2001/0046987 A1
	BJ1	WO-01-47949-A1	07-05-2001	Ajinomoto Co., Inc.		See US 6818243 B2
	BK1	DE-19962924-A1	07-05-2001	Bayer AG		See US 7157456 B2
	BL1	AU-744002	02-14-2002	Merck Patent GmbH		
	BM1	WO-02/25210-A1	03-28-2002	Sht Co., Ltd.		
	BN1	DE-10105989-A1	08-14-2002	Bayer AG		See US 7034017 B2
	BO1	WO-02/064575-A1	08-22-2002	Bayer AG		See US 7034017 B2
	BP1	WO-02/070520-A1	09-12-2002	Bayer Aktiengesellschaft		See US 2004/0162427 A1
	BQ1	WO-02/070484-A1	09-12-2002	Bayer Aktiengesellschaft		See US 2005/0261502 A1
	BR1	WO-02/070485-A1	09-12-2002	Bayer Aktiengesellschaft		See US 2006/0154969 A1
	BS1	WO-02/079195-A1	10-10-2002	Bayer Aktiengesellschaft		See US 7,078,417 B2
	BT1	WO-02/079196-A1	10-10-2002	Bayer Aktiengesellschaft		See US 7,129,255 B2
	BU1	DE-10129725-A1	01-02-2003	Bayer AG		See US 2004/242660 A1
	BV1	WO-03/000256-A1	01-03-2003	Bayer HealthCare AG		See US 2004/242660 A1
	BW1	WO-03/08384-A1	01-30-2003	Bayer Aktiengesellschaft		See US 7,045,631 B2
	BX1	WO-03/053441-A1	07-03-2003	Bayer Aktiengesellschaft		See US 7,109,218 B2
	BY1	WO-2004/060887-A1	07-22-2004	Bayer HealthCare AG et al.		See US 2007/149522 A1
	BZ1	WO-2005/060940-A1	05-07-2005	Bayer HealthCare AG et al.		See US 2008/026057 A1
	BA2	DE-10355461-A1	06-23-2005	Bayer HealthCare AG et al.		See US 2008/026057 A1
	BB2	WO-2006/072367-A1	07-13-2006	Bayer HealthCare AG et al.		See US 2007/026065 A1
	BC2	WO-2005/068456-A1	07-28-2005	Bayer HealthCare AG et al.		See US 7351823 B2
	BD2	WO-2006/079474-A1	08-03-2006	Bayer HealthCare AG et al.		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	4	of	10	Attorney Docket Number	11987-00043-US

	BE2	WO-2007/036306-A1	04-05-2007	Bayer HealthCare AG et al.		See Abstract
	BF2	WO-2007/039134-A1	04-12-2007	Bayer HealthCare AG et al.		See Abstract
	BG2	WO-2007/039132-A1	04-12-2007	Bayer HealthCare AG et al.		See Abstract
	BH2	WO-2007/039122-A2	04-12-2007	Bayer HealthCare AG et al.		See Abstract
	BI2	WO-2007/042146-A1	04-19-2007	Bayer HealthCare AG et al.		See Abstract
	BJ2	WO-2008/012002-A1	01-31-2008	Bayer HealthCare AG et al.		See Abstract
	BK2	WO-2008/052671-A1	05-08-2008	Bayer HealthCare AG et al.		See Abstract

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Application Number</b>	10/580,711-Conf. #3892
				<b>Filing Date</b>	May 18, 2007
				<b>First Named Inventor</b>	Klaus Benke
				<b>Art Unit</b>	1615
				<b>Examiner Name</b>	Woodward, Michael P.
<b>Sheet</b>	5	of	10	<b>Attorney Docket Number</b>	11987-00043-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	BONO, F., et al., "Human Umbilical Vein Endothelial Cells Express High Affinity Receptors for Factor Xa", Journal of Cellular Physiology, 1997, Vol. 172, pp. 36-43.	
	CB	COCKS, T. M., et al., "Protease-Activated Receptors: Sentries for Inflammation", Tips, 2000, Vol. 21, pp. 103-108.	
	CC	ROSS, R., "Atherosclerosis- An Inflammatory Disease", New England J. of Medicine, 1999, Vol. 340, No. 2, pp. 115-126.	
	CD	NAKATA, M., et al., "DX9065a an Xa Inhibitor, Inhibits Prothrombin-Induced A549 Lung Adenocarcinoma Cell Proliferation", Cancer Letters, 1998, Vol. 122, pp. 127-133.	
	CE	KAISER, B., et al., "A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats", Thrombosis Research, 2000, Vol. 98, pp. 175-185.	
	CF	ALTIERI, D. C., et al., "Identification of Effector Cell Protease Receptor-1", The Journal of Immunology, 1990, Vol. 145, No. 1, pp. 246-253.	
	CG	COUGHLIN, S. R., "Thrombin Signalling and Protease-Activated Receptors", Nature, 2000, Vol. 407, pp. 258-264.	
	CH	ORNSTEIN, D. L., et al., "Cancer, Thrombosis, and Anticoagulants", Current Opinion in Pulmonary Medicine, 2000, Vol. 6, pp. 301-308.	
	CI	DABBAGH, K., et al., "Thrombin Stimulates Smooth Muscle Cell Procollagen Synthesis and mRNA Levels via a PAR-1 Mediated Mechanism", Thrombosis and Haemostasis, vol. 79, no.2 1997, pp. 405-409.	
	CJ	HERAULT, J-P., et al., "Activation of Human Vascular Endothelial Cells by Factor Xa: Effect of Specific Inhibitors", Biochemical Pharmacology, 1999, Vol. 57, pp. 603-610.	
	CK	LEVEUGLE, B., et al., "Heparin Oligosaccharides that Pass the Blood- Brain Barrier Inhibit $\beta$ -Amyloid Precursor Protein Secretion and Heparin Binding to $\beta$ -Amyloid Peptide", Journal of Neurochemistry, 1998, Vol. 70, No. 2, pp. 736-744.	
	CL	MOLINO, M., et al., "Differential Expression of Functional Protease-Activated Receptor-2 (PAR-2) in Human Vascular Smooth Muscle Cells", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, 1998, pp. 825-832.	
	CM	PLESCIA, J., et al., "Activation of MAC-1 (CD11b/CD18)-Bound Factor X by Release Cathepsin G Defines an Alternative Pathway of Leucocyte Initiation of Coagulation", Biochem. J., 1996, Vol. 319, pp. 873-879.	
	CN	HOWELLS, G. L., et al., "Proteinase-Activated Receptor-2: Expression by Human Neutrophils", Journal of Cell Science, 1997, Vol. 110, pp. 881-887.	
	CO	HERBERT, J.-M., et al., "Effector Protease Receptor 1 Mediates the Mitogenic Activity of Factor Xa for Vascular Smooth Muscle Cells in Vitro and In Vivo", J. Clin. Invest., 1998, Vol. 101, no. 5, pp. 993-1000.	
	CP	DONNELLY, K. M., et al., "Ancylostoma caninum Anticoagulant Peptide Blocks Metastasis In Vivo and Inhibits Factor Xa Binding to Melanoma Cells In Vitro", Thromb Haemost, 1998, Vol. 79, pp. 1041-1047.	
	CQ	RAGOSTA, M., et al., "Specific Factor Xa Inhibition Reduces Restenosis After Balloon Angioplasty of Atherosclerotic Femoral Arteries in Rabbits", Circulation, 1994, Vol. 89, No. 3, pp. 1262-1271.	
	CR	ZHANG, Y., et al., "Tissue Factor Controls the Balance of Angiogenic and Antiangiogenic Properties of Tumor Cells in Mice", J. Clin. Invest., 1994, Vol. 94, pp. 1320-1327.	

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	6	of	10	Attorney Docket Number	11987-00043-US

CS	GREEN, D., et al., "Lower Mortality in Cancer Patients Treated with Low-Molecular-Weight Versus Standard Heparin", The Lancet, 1992, Vol. 339, p. 1476.	
CT	KO, F. N., et al., "Coagulation Factor Xa Stimulates Platelet-Derived Growth Factor Release and Mitogenesis in Cultured Vascular Smooth Muscle Cells of Rat", J. Clin. Invest., 1996, Vol. 98, No. 6, pp. 1493-1501.	
CU	KAKKAR, A. K., et al., "Antithrombotic Therapy in Cancer", BMJ, 1999, Vol. 3318, pp. 1571-1572.	
CV	GASIC, G. P., et al., "Coagulation Factors X, Xa, and Protein S as Potent Mitogens of Cultured Aortic Smooth Muscle Cells", Proc. Natl. Acad. Sci. USA, 1992, Vol. 89, pp. 2317-2320.	
CW	CIRINO, G., et al., "Factor Xa as an Interface Between Coagulation and Inflammation: Molecular Mimicry of Factor Xa Association with Effector Cell Protease Receptor-1 Induces Acute Inflammation In Vivo", J. Clin. Invest., 1997, Vol. 99, No. 10, pp. 2446-2451.	
CX	SENDEN, N. H. M., et al., "Factor Xa Induces Cytokine Production and Expression of Adhesion Molecules by Human Umbilical Vein Endothelial Cells", The Journal of Immunology, 1998, Vol. 161, pp. 4318-4324.	
CY	PAPAPETROPOULOS, A., et al., "Hypotension and Inflammatory Cytokine Gene Expression Triggered by Factor Xa-Nitric Oxide Signaling", Proc. Natl. Acad. Sci. USA, 1998, Vol. 95, pp. 4738-4742.	
CZ	CAMERER, E., et al., "Tissue Factor- and Factor X-dependent Activation of Protease-Activated Receptor 2 by Factor VIIa", PNAS, 2000, Vol. 97, No. 10, pp. 5255-5260.	
CA1	DONOVAN, F. M., et al., "Thrombin Induces Apoptosis in Cultured Neurons and Astrocytes via a Pathway Requiring Tyrosine Kinase and RhoA Activities", The Journal of Neuroscience, 1997, Vol. 17, No. 14, pp. 5316-5326.	
CB1	LINDNER, J. R., et al., "Delayed Onset of Inflammation in Protease-Activated Receptor-2-Deficient Mice", The Journal of Immunology, 2000, pp. 6504-6510.	
CC1	BOUCHARD, B. A., et al., "Effector Cell Protease Receptor-1, a Platelet Activation-dependent Membrane Protein, Regulates Prothrombinase-catalyzed Thrombin Generation", The Journal of Biological Chemistry, 1997, Vol. 272, No. 14, pp. 9244-9251.	
CD1	MOLINO, M., et al., "Endothelial Cell Thrombin Receptors and PAR-2", The Journal of Biological Chemistry, 1997, Vol. 272, No. 17, pp. 11133-11141.	
CE1	NICHOLSON, A. C., et al., "Effector Cell Protease Receptor-1 Is a Vascular Receptor for Coagulation Factor Xa", The Journal of Biological Chemistry, 1996, Vol. 271, No. 45, pp. 28407-28413.	
CF1	WATSON, D. J., et al., "Heparin-Binding Properties of the Amyloidogenic Peptides A $\beta$ and Amylin", The Journal of Biological Chemistry, 1997, Vol. 272, No. 50, pp. 31617-31624.	
CG1	TUSZYNSKI, G. P., et al., "Isolation and Characterization of Antistasin", The Journal of Biological Chemistry, 1987, Vol. 262, No. 20, pp. 9718-9723.	
CH1	KRANZHÖFER, R., et al., "Thrombin Potently Stimulates Cytokine Production in Human Vascular Smooth Muscle Cells but Not in Mononuclear Phagocytes", Circulation Research, 1996, Vol. 79, No. 2, pp. 286-294.	
CI1	SCHWARTZ, R. S., et al., "Neointimal Thickening After Severe Coronary Artery Injury is Limited by Short-term Administration of a Factor Xa Inhibitor", Circulation, 1996, Vol. 93, No. 8, pp. 1542-1548.	
CJ1	ABENDSCHEIN, D. R., et al., "Inhibition of Thrombin Attenuates Stenosis After Arterial Injury in Minipigs", JACC, 1996, Vol. 28, No. 7, pp. 1849-1855.	
CK1	CARMELIET, P., et al., "Gene Manipulation and Transfer of the Plasminogen and Coagulation System in Mice", Seminars in Thrombosis and Hemostasis, 1996, Vol. 22, No. 6, pp. 525-542.	
CL1	STOUFFER, G. A., et al., "The Role of Secondary Growth Factor Production in Thrombin-Induced Proliferation of Vascular Smooth Muscle Cells", Seminars in Thrombosis and	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	7	of	10	Attorney Docket Number	11987-00043-US

		Hemostasis, 1998, Vol. 24, No. 2, pp. 145-150.	
	CM1	BEVILACQUA, M. P., et al., "Inducible Endothelial Functions in Inflammation and Coagulation", Seminars in Thrombosis and Hemostasis, 1987, Vol. 13, No. 4, pp. 425-433.	
	CN1	Riedl, B., et al., "Recent Developments with Oxazolidinone Antibiotics", Exp. Opin. Ther. Patents, 1999, Vol. 9, No. 5, pp. 625-633.	
	CO1	Barbachyn, M.R., et al., "Identification of Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity", J. Med. Chem., 1996, Vol. 39, pp. 680-685.	
	CP1	TUCKER, J. A., et al, "Piperazinyl Oxazolidinone Antibacterial Agents Containing a Pyridine, Diazene, or Triazene Heteroaromatic Ring", J. Med. Chem. 1998, Vol. 41, pp. 3727-3735.	
	CQ1	Brickner, S.J., et al., "Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential treatment of Multidrug-Resistant Gram-Positive Bacterial Infections" J. Med. Chem., 1996, Vol. 39, pp. 673-679	
	CR1	GREGORY, W.A., et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group", J. Med. Chem., 1989, Vol. 32, No. 8, pp. 1673-1681.	
	CS1	BERRY, C. N., et al., "Antithrombotic Actions of Argatroban in Rat Models of Venous, 'Mixed' and Arterial Thrombosis, and its Effects on the Tail Transection Bleeding Time", Br. J. Pharmacol., 1994, Vol. 113, pp. 1209-1214.	
	CT1	MENG, K., et al., "Effect of Acetylsalicylic Acid of Experimentally Induced Arterial Thrombosis in Rats", Naunyn-Schmiedeberg's Arch. Pharmacol., 1977, Vol. 301, pp. 115-119.	
	CU1	CHERN, J.W., et al., "Studies on Quinazolines IX:1 Fluorination Versus 1,2-Migration on the Reaction of 1,3-Bifunctionalized Amino-2-Propanol with DAST", Tetrahedron Lett., 1998, Vol. 39, pp. 8483-8486.	
	CV1	SHAKESPEARE, W. C., et al., "Palladium-Catalyzed Coupling of Lactams with Bromobenzenes", Tetrahedron Lett., 1999, Vol. 40, pp. 2035*2038.	
	CW1	RENGER, B., et al., "Direkte N-Arylierung von Amiden: Eine Verbesserung der Goldberg-Reaktion", Synthesis, 1985, pp. 856-860.	
	CX1	AEBISCHER, E., et al., "Synthesis of N-Arylrolipram Derivatives - Potent and Selective Phosphodiesterase-IV Inhibitors - by Copper Catalyzed Lactam-Aryl Halide Coupling", Heterocycles, 1998, Vol. 48, No. 11, pp. 2225-2229.	
	CY1	PFEIL, E., et al., "β-Aminoäthylisierung von Indol und 2-methylindol", Angew. Chem., 1967, Vol. 79, No. 4, pp. 188-189.	
	CZ1	ZIEGLER, C. B., et al., "Synthesis of Some Novel 7-Substituted Quinolonecarboxylic Acids via Nitroso and Nitrono Cycloadditions", J. Heterocycl. Chem., 1988, Vol. 25, No. 2, pp. 719-723.	
	CA2	BARTOLI, G., et al, "Electronic and Steric Effects in Nucleophilic Aromatic Substitution. Reaction by Phenoxides as Nucleophiles in Dimethyl Sulfoxide", J. Org. Chem., 1975, Vol. 40, No. 7, pp. 872-874.	
	CB2	REPPE, et al., "N-p-Merthoxyphenyl-pyrrolidon", Justus Liebigs Ann. Chem., 1955 Vol. 596, p. 208.	
	CC2	LUVALLE, J.E., et al., "Oxidation Processes. XXI.1 The Autoxidation of the p-Phenylenediamines", J. Am. Chem. Soc., 1948, Vol. 70, pp. 2223-2233.	
	CD2	SNYDER, H.R., et al., "Imidazo[4,5-f]quinolines III: Antibacterial 7-Methyl-9-(substituted Arylamino)imidazo[4,5-f]quinolines", J. Pharm. Sci., 1977, Vol. 66, pp. 1204-1406.	
	CE2	ADAMS, R., et al., "Sulfanilamide Derivatives. I", J. Am. Chem. Soc. 1939, Vol. 61, pp. 2342-2349.	
	CF2	KHANNA, I.K. , et al., "1,2-Diarylpurroles as Potent and Selective Inhibitors of Cyclooxygenase-2", J. Med. Chem., 1997, Vol. 40, pp. 1619-1633.	
	CG2	GUTCAIT, A., et al., "Studies on Quinazolines. 6.1 Asymmetric Synthesis of (S)-(+)- and (R)-(-)-3-[[4-(2-Methoxyphenyl)piperazin-1-yl]methylthio-2,3,-dihydromidazo[1,2-c]quinazolines",	

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Application Number</b>	10/580,711-Conf. #3892	
			<b>Filing Date</b>	May 18, 2007	
			<b>First Named Inventor</b>	Klaus Benke	
			<b>Art Unit</b>	1615	
			<b>Examiner Name</b>	Woodward, Michael P.	
			<b>Attorney Docket Number</b>	11987-00043-US	
<b>Sheet</b>	8	of	10		

		Tetrahedron Asym., 1996, Vol. 7, No. 6, pp. 1641-1648.	
	CH2	GRELL, W., et al., "Repaglinide and Related Hypoglycemic Benzoic Acid Derivatives", J. Med. Chem., 1998, Vol. 41, pp. 5219-5246.	
	CI2	ARTICO, M. et al., "Research on Compounds with Antitubercular Activity", Farmaco Ed. Sci. 1969, Vol. 24, pp. 179-190.	
	CJ2	DANKWARDT, S. M., et al., "Nonpeptide Bradykinin Antagonist Analogs based on a Model of a Sterling-Winthrop Nonpeptide Bradykinin Antagonist Overlapped with Cyclic Hexapeptide Bradykinin Antagonist Peptides", Bioorg. Med. Chem. Lett., 1997, Vol. 7, No. 14, pp. 1921-1926.	
	CK2	REPPE, et al., "N-6-Aminohexyl-pyrrolidone", Justus Liebigs Ann. Chem. 1955, Vol. 596, pp. 204.	
	CL2	BOUCHET, P., et al., "σ Values of N-Substituted Azoles", J. Chem. Soc. Perkin Trans., 1974, Vol. 2, pp. 449-451.	
	CM2	SURREY, A. R., et al., "The Preparation of N-Benzyl-3-Morpholones and N-Benzyl-3-Homomorpholones from N-(Hydroxyalkyl)-chloroacetamides" J. Amer. Chem. Soc., 1955, Vol. 77, pp. 633-636.	
	CN2	TONG, L.K.J., et al., "The Mechanism of Dye Formation in Color Photography. VII. Intermediate Bases in the Deamination of Quinonediimines" J. Amer. Chem. Soc. 1960, Vol. 82, 1988-2001.	
	CO2	DELANDE, S.A., "Heterocycles", Chemical Abstracts, American Chemical Society, 1979, Vol. 90, pp. 663.	
	CP2	BOTS, M., et al., Coagulation and Fibrinolysis Markers and Risk of Dementia, Haemostasis, Vol. 28 (1998); pp. 216-222.	
	CQ2	BENZAKOUR, O., et al., "Cellular and molecular events in atherogenesis; basis for pharmacological and gene therapy approaches to stenosis," Cellular Pharmacology, 1996, Vol. 3, pp. 7-22.	
	CR2	KANTHOU, C., et al., "Cellular effects of thrombin and their signalling pathways," Cellular Pharmacology, Vol. 2 (1995); pp. 293-302.	
	CS2	KAISER, B., et al., "Antiproliferation Action of Factor Xa Inhibitors in a Rat Model of Chronic Restenosis," Abstracts of the XVIIIth Congress of the International Society on Thrombosis and Haemostasis, August 1999, p. 144.	
	CT2	TYRRELL, D., et al., "Heparin in Inflammation: Potential Therapeutic Applications Beyond Anticoagulation," Advances in Pharmacology, Vol. 46 (1999); pp. 151-208.	
	CU2	SMIROVA, I., et al., "Thrombin Is an Extracellular Signal that Activates Intracellular Death Protease Pathways Inducing Apoptosis in Model Motor Neurons," J. Neurobiology, Vol. 36 (1998); pp. 64-80.	
	CV2	BONO, F., et al., "Factor Xa Activates Endothelial Cells by a Receptor Cascade Between EPR-1 and PAR-2," Arterioscler Thromb Vasc Biol., Nov. 2000; pp. 1-6.	
	CW2	LALA, P. et al, "Role of Nitric Oxide in tumor progression: Lessons Learned from Experimental Tumors," Cancer and Metastasis Review, Vol. 17, pages 91-106 (1998).	
	CX2	GOLUB, T., et al., "Molecular Classification of Cancer Science (1999), Vol. 286, 531-537.	
	CY2	FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on 2003-09-23]. Retrieved from the internet, URL: <a href="http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html">http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html</a> .	
	CZ2	Ullman's Encyclopedia of Industrial Chemistry, Fifth Revised Ed., Editors: Elvers, B., Hawkins, S., VCH Verlagsgesellschaft mbH, Weinheim, 1995-1996, Ch. 5, 488-506.	
	CA3	ZHU, B., Scarborough, R., "Recent Advances in Inhibitors of Factor Xa in the Prothrombinase Complex," Curr. Opin. Card. Pul. Ren. Inv. Drugs, 1:63-87 (1999).	
	CB3	UZAN, A., "Antithrombotic Agents," Emerging Drugs: The Prospect for Improved Medicines,"	



Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	9	of	10	Attorney Docket Number	11987-00043-US

		3: 189-208 (1998).	
CC3	KAISER, B., "Thrombin and Factor Xa Inhibitors," <i>Drugs of the Future</i> , 23: 423-426 (1998).		
CD3	AL-OBEIDI, F., Ostrem, J., "Factor Xa Inhibitors," <i>Expert Opin. Therapeutic Patents</i> , 9: 931-953 (1999).		
CE3	AL-OBEIDI, F., Ostrem, J., "Factor Xa Inhibitors by Classical and Combinatorial Chemistry," <i>DDT</i> , 3: 223-231 (May 1998).		
CF3	HAUPTMANN, J., et al., "Synthetic Inhibitors of Thrombin and Factor Xa: From Bench to Bedside," <i>Thrombosis Research</i> , 93: 203-241 (1999).		
CG3	Pschyrembel, Klinisches Wörterbuch, 257. Auflage, 1994, Walter de Gruyter Verlag, p. 199-200, Stichwort "Blutgerinnung."		
CH3	Rompp Lexikon Chemie, Ver. 1.5, 1998, Georg Thieme Verlag Stuttgart, Stichwort "Blutgerinnung" Lubert Stryer, Biochemie, Spektrum der Wissenschaft Verlagsgesellschaft mbH Heidelberg, 1990, p. 259.		
CI3	Pschyrembel, Klinisches Wörterbuch, 257. Auflage, 1994, Walter de Gruyter Verlag, p. 610, Stichwort "Heparin."		
CJ3	Rompp Lexikon Chemie, Ver. 1.5, 1998, Georg Thieme Verlag Stuttgart, Stichwort "Heparin."		
CK3	Pschyrembel, Klinisches Wörterbuch, 257. Auflage, 1994, Walter de Gruyter Verlag, p. 292, Stichwort "Cumarinderivate."		
CL3	BECKER, M.R., et al., "Synthesis, Sar and in Vivo Activity of Novel Thienopyridine Sulfonamide Pyrrolidinones as Factor Xa Inhibitors," <i>Bioorganic and Medicinal Chemistry Letters</i> , 9: 2753-2758 (1999).		
CM3	LINDER, J., et al., "Delayed Onset of Inflammation in Protease-Activated Receptor-2-Deficient Mice," <i>J. Immunology</i> , 2000, pp. 6504-6510.		
CN3	CIRINO, G. et al. "Inflammation-Coagulation Network: Are Serine Protease receptors the knot?; <i>Tips</i> ; 200, vol.21, pp. 170-172		
CO3	ROEHRIG, S. et al. Discovery of the Novel Antithrombotic Agent 5-Chloro-N-((5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methylthiophene-2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor. <i>J. Med. Chem.</i> 48, 22. Sept. 2005, pp. 5900-5908.		
CP3	CAIRA, M. Crystalline Polymorphism Of Organic Compounds. Springer Verlag Berlin Heidelberg 198, 1998, pp. 163-208.		
CQ3	HANCOCK, B. et al. Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. <i>Journal of Pharmaceutical Science</i> . 86, 1 (1997-1), pp. 1-12.		
CR3	CHIOU, W.L. et al. Pharmaceutical Applications of Solid Dispersion Systems. <i>Journal of Pharmaceutical Sciences</i> 60, (1971). 128-1302.		
CS3	FORD, J.L. The Current Status of Solid Dispersions. <i>Pharm Acta Helv.</i> 61, (1986)69-88.		
CT3	RASENACK, N. et al. Poorly Water-soluble Drugs for Oral Delivery- A Challenge for Pharmaceutical Development. <i>Pharmazeutische Industrie</i> 67, Nr. 5 (2005), 583-591.		
CU3	BREITENBACH, J. Melt extrusion: from process to drug delivery technology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> 54 (2002) 107-117.		
CV3	BREITENBACH, J. Feste Loesungen durch Schmelzextrusion - ein integriertes Herstellkonzept. <i>Pharmazie in unserer Zeit</i> 29 (2000), 46-49.		
CW3	<a href="http://familydoctor.org/online/famdocen/home/common/heartdisease/basics/290.html">http://familydoctor.org/online/famdocen/home/common/heartdisease/basics/290.html</a>		
CX3	KUBITZA, et al., Multiple dose escalation study Investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects, <i>Blood</i> , Vol 102:11:16 Nov. 2003, pg. 811a.		
CY3	KUBITZA, et al., ABSTRACT 3010, Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects, <i>Blood</i> , Vol 102:11. 16 Nov.2003, pg. 813a.		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/580,711-Conf. #3892
				Filing Date	May 18, 2007
				First Named Inventor	Klaus Benke
				Art Unit	1615
				Examiner Name	Woodward, Michael P.
Sheet	10	of	10	Attorney Docket Number	11987-00043-US

	CZ3	REPPE, et al., Justus Liebigs Ann. Chem. 596, 1955, p. 209.	
	CA4	WONG et al., The Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 1 (2000) pages 212-218.	
	CB4	ROSS, Russell, "Atherosclerosis -- An Inflammatory Disease," The New England Journal of Medicine; vol. 340, no. 2; pp 115-126 (Jan. 14, 1999).	
	CC4	PERZBORN, E. et al. <i>In vitro</i> and <i>in vivo</i> studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. Journal of Thrombosis and Haemostasis 3, 3, March 2005, pp. 514-521.	
	CD4	ESPINOSA, G. et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Annals of the Rheumatic Diseases, 63, 6, June 2004, pp. 730-736.	
	CE4	BONOMINI, V. et al. A New Antithrombotic Agent in the Treatment of Acute Renal Failure Due to Hemolytic-Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Nephron 37, 1984, 2, 144.	
	CF4	SINHA, U. et al. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. European Journal of Pharmacology 2000, 395, 51-59.	
	CG4	BETZ, A. Recent advances in Factor Xa inhibitors. Expert Opinion Ther. Patents 2001, 11, 1007-1017.	
	CH4	TAN, K.T. et al. Factor X inhibitors. Expert Opinion Investig. Drugs 2003, 12, 799-804.	
	CI4	RUEF, J. et al. New antithrombotic drugs on the horizon. Expert Opinion Investig. Drugs 2003, 12, 781-797.	
	CJ4	SAMAMA, M.L. Synthetic direct and indirect factor Xa inhibitors. Thrombosis Research 2002, 106, V267-V273.	
	CK4	QUAN, M.L. The race to an orally active Factor Xa inhibitor: Recent advances. Current Opinion in Drug Discovery & Development 2004, 7, 460-469.	
	CL4	The Ephesus Study, Blood 2000, 96, 490a	
	CM4	The Penthifra Study, Blood 2000, 96, 490a	
	CN4	The Pentamaks Study, Blood 2000, 96, 490a-491a.	
	CO4	The Pentathlon 2000 Study, Blood 2000, 96, 491a	
	CP4	LEADLEY, R.J. Coagulation Factor Xa Inhibition: Biological Background and Rationale. Current Topics in Medical Chemistry 2001, 1, 151-159.	
	CQ4	GILLIGAN, D.M. et al. The Management of Atrial Fibrillation. The American Journal of Medicine, vol. 101, (4) 1996, 413-421.	
	CR4	KUBITZA, D. et al. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opinion on Investig. Drugs, vol. 15, (8) 2006, pp. 843-855.	
	CS4	WILLIAMS, E.M. Vaughan. Classificating anti-arrhythmic drugs. In: Cardiac Arrythias- Proceedings of a symposium, sandoe E., soedertaeje: Astra (1970), pp. 449-469.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.